DOPAMINE MODULATION OF LIMBIC CORTICOACCUMBENS SYSTEM

Information

  • Research Project
  • 6392956
  • ApplicationId
    6392956
  • Core Project Number
    R01MH063498
  • Full Project Number
    5R01MH063498-02
  • Serial Number
    63498
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/9/2000 - 23 years ago
  • Project End Date
    8/31/2005 - 18 years ago
  • Program Officer Name
    WINSKY, LOIS M.
  • Budget Start Date
    9/1/2001 - 22 years ago
  • Budget End Date
    8/31/2002 - 21 years ago
  • Fiscal Year
    2001
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/18/2001 - 22 years ago
Organizations

DOPAMINE MODULATION OF LIMBIC CORTICOACCUMBENS SYSTEM

DESCRIPTION: (Adapted from the Investigator's Abstract) Psychostimulant abuse in humans is known to produce states similar to both positive and negative symptoms of schizophrenia. Studies in rats have suggested that hyper-dopaminergic activity in subcortical structures such as nucleus accumbens leads to behavioral abnormality that may have relevance to positive symptoms. Emotional and cognitive deficits that characterize negative symptoms have been recently demonstrated in monkeys similarly treated with low doses of amphetamine and that in many ways resemble those identified in human amphetamine abusers. These cognitive deficits are believed to result from a dysfunction in the prefrontal cortex, thus linking to a clinical state of hypofrontality. A basic dysfunction of prefrontal-accumbens circuits is thought to be critical to the cognitive dysfunction, negative affect and abnormal reward-related behavior that is characteristic of schizophrenia and drug abuse. My working hypotheses is that in amphetamine treated rats there exists deficits in the excitatory drive from the limbic afferents from the entorhinal cortex and the mediodorsal thalamus to the prefrontal cortex and/or deficits in the dopamine modulation of these excitatory afferents. Thus the proposed experiments using in vivo intracellular recording and labeling techniques will compare and contrast information arising intracortically (eg entorhinal cortex; aim 1) and subcortically (eg mediodorsal thalamus; aim 2), the latter of which transmits basal ganglia outflow back to the prefrontal cortex. Lastly cortical processing in influencing basal ganglia outflow from the nucleus accumbens. I predict attenuated intracortical processing (aim 1) to occur in conjunction with an augmented basal ganglia feedback circuit, as marked by increases in both mediodorsal thalamus-evoked activity in prefrontal cortex neurons (aim 2) and prefrontal cortex-evoked activity in nucleus accumbens neurons (aim 3), in amphetamine treated rats. The proposed study is of particular interest with respect to the deficit syndrome in schizophrenia and possibly other mental disorders such as drug addiction associated with negative affect and depression.

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    R01
  • Administering IC
    MH
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    228000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    242
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIMH:228000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MCP HAHNEMANN UNIVERSITY
  • Organization Department
    BIOLOGY
  • Organization DUNS
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191021192
  • Organization District
    UNITED STATES